ViGenCell (A308080) Stock Overview
Provides immune cell therapy in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A308080 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ViGenCell Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,340.00 |
| 52 Week High | ₩17,360.00 |
| 52 Week Low | ₩2,760.00 |
| Beta | 0.84 |
| 1 Month Change | -17.08% |
| 3 Month Change | -49.76% |
| 1 Year Change | 64.31% |
| 3 Year Change | -32.32% |
| 5 Year Change | n/a |
| Change since IPO | -82.05% |
Recent News & Updates
Shareholder Returns
| A308080 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 5.5% | 1.4% | 8.3% |
| 1Y | 64.3% | 35.2% | 130.0% |
Return vs Industry: A308080 exceeded the KR Biotechs industry which returned 36.5% over the past year.
Return vs Market: A308080 underperformed the KR Market which returned 126.6% over the past year.
Price Volatility
| A308080 volatility | |
|---|---|
| A308080 Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A308080's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A308080's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 64 | Kim Tai Gyu | www.vigencell.com |
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.
ViGenCell Inc. Fundamentals Summary
| A308080 fundamental statistics | |
|---|---|
| Market cap | ₩109.47b |
| Earnings (TTM) | -₩12.56b |
| Revenue (TTM) | ₩278.95m |
Is A308080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A308080 income statement (TTM) | |
|---|---|
| Revenue | ₩278.95m |
| Cost of Revenue | ₩274.65m |
| Gross Profit | ₩4.30m |
| Other Expenses | ₩12.56b |
| Earnings | -₩12.56b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -612.64 |
| Gross Margin | 1.54% |
| Net Profit Margin | -4,502.18% |
| Debt/Equity Ratio | 13.0% |
How did A308080 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 13:56 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ViGenCell Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.